TheStreet upgraded shares of Entellus Medical (NASDAQ:ENTL) from a d rating to a c- rating in a research note published on Thursday.

A number of other brokerages have also recently commented on ENTL. William Blair cut shares of Entellus Medical from an outperform rating to a market perform rating in a report on Friday, December 8th. ValuEngine raised shares of Entellus Medical from a sell rating to a hold rating in a report on Thursday, December 7th. Zacks Investment Research raised shares of Entellus Medical from a sell rating to a buy rating and set a $23.00 target price for the company in a report on Monday, October 9th. Canaccord Genuity reaffirmed a hold rating and set a $17.00 target price on shares of Entellus Medical in a report on Tuesday, October 17th. Finally, Piper Jaffray Companies reaffirmed a buy rating and set a $21.00 target price on shares of Entellus Medical in a report on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $20.40.

Entellus Medical (NASDAQ ENTL) opened at $24.63 on Thursday. Entellus Medical has a twelve month low of $11.47 and a twelve month high of $24.88. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32.

In other news, VP Kevin L. Mensink sold 10,000 shares of the stock in a transaction on Monday, October 16th. The shares were sold at an average price of $18.29, for a total value of $182,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Timothy B. Petrick sold 2,000 shares of the stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $18.00, for a total transaction of $36,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 168,469 shares of company stock valued at $3,718,611. Corporate insiders own 7.70% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after purchasing an additional 2,594 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Entellus Medical by 61.7% during the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after acquiring an additional 2,635 shares during the last quarter. First Mercantile Trust Co. boosted its position in shares of Entellus Medical by 45.3% during the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after acquiring an additional 2,557 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Entellus Medical by 145.1% during the third quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after acquiring an additional 5,605 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Entellus Medical by 61.7% during the second quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock worth $196,000 after acquiring an additional 4,533 shares during the last quarter. 78.76% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/entellus-medical-entl-raised-to-c-at-thestreet/1768953.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.